For people with type 2 diabetes and chronic kidney disease (CKD), semaglutide (Ozempic) reduced the risk of major kidney events and death from cardiovascular causes, the phase III FLOW trial showed.

Inside the human body, a silent battle rages between diabetes and kidney function, with devastating consequences many never see coming. Recent medical research has uncovered alarming evidence about ...

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA's ...

An international study found that finerenone slows kidney function decline and reduces the risk of serious kidney and ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with ...

People living with both obesity and type 2 diabetes face a sharply elevated risk of heart failure, atherosclerotic ...

For years, metformin has been the go-to first-line oral medication for patients newly diagnosed with type 2 diabetes. But with the growing popularity and effectiveness of medications like semaglutide ...

ST. PAUL, Minn., Nov. 6 (UPI) --Positive results from a late-stage clinical trial released Thursday have raised hopes that type 1 diabetes patients who suffer from chronic kidney disease will have a ...

Sofia Tsanou and Michaela Smith founded a charity and support group for kidney patients.

Despite treatment advances, kidney disease burden remained unchanged over the past decade ...